• Info
  • Home
  • About
  • Editorial Board
  • Archive
  • Research Topics
  • View Some Authors
  • Review Guidelines
  • Subscribe to Alerts
  • Search
  • Article Type

    Publication Date

  • Author Info
  • Why Submit?
  • Fees
  • Article Types
  • Author Guidelines
  • Submission Checklist
  • Contact Editorial Office
  • Submit Manuscript
Start date should be earlier than end date. OK Please enter the date in dd/mm/yyyy format or use the calendar icon to the left of the date field.

About

Facts

Specialty Chief Editor/s:  John de Wit, The University of New South Wales, Australia
Frank Miedema, University Medical Centre Utrecht, Netherlands

Indexed in: PubMed, PubMed Central, Scopus, Google Scholar, DOAJ, CrossRef

PMCID: coming soon for all published articles

Mission Statement

HIV and AIDS is a specialty section of Frontiers in Immunology and Frontiers in Public Health.

Three decades of HIV/AIDS research have brought understanding of and insight into all aspects of the immune pathology, anti-viral immunity, and the diverse manifestations of this disease. With unprecedented speed, antiretrovirals became available that target different steps in the HIV replication cycle, which are now effectively used in combination therapy. Combination antiretroviral therapy also reduces the likelihood of onward HIV transmission, and HIV treatment is a crucial component of HIV prevention, in combination with public health approaches, in particular the promotion of regular HIV testing and safe practices. Despite enormous international collaborative efforts and detailed research into neutralising antibodies and HIV specific cellular immunity, effective immunotherapy or an efficacious vaccine are not yet available. Major aspects of HIV infection are still not well understood, and much remains to be done to ensure affected people and communities benefit from the knowledge that has accumulated and that drives clinical and public health innovation.

In the past decade, our thinking about HIV pathogenesis has significantly changed, and it is now believed that not the loss of CD4+ T cells through HIV cytopathic infection, but the chronic inflammation that HIV induces, may eventually cause immune deficiency and non-AIDS diseases such as cardiovascular disease and inflammation induced artherosclerosis. However , the virus-host interactions that differ pathologically from non-pathological HIV and SIV are still unknown. Chronic immune activation and inflammation are considered major drivers of the disease, but it is unclear which interactions of HIV with the innate immune system via which receptors are critical. It is suggested that inflammation is also the cause of HIV-associated non-AIDS diseases and, given that even in HAART-controlled HIV infections the risk for non-AIDS disease is high, inflammation may be a therapeutic target in HIV infection. HIV-specific immunity does affect viral load and slows down disease progression, but eventually fails in almost all patients.

Better understanding the pathogenesis of HIV in the host and the dissemination of HIV in the population are both essential to effective control of the epidemic. Research on pathogenesis and public health address two sides of the same coin and underpin the effective control of HIV-associated disease and the spread of HIV in the population. As an innovative collaboration and cross-fertilization between Frontiers in Immunology and Frontiers in Public Health, the HIV and AIDS specialty section aims to bring together studies on pathogenesis and on public health aspects. Reflecting this broadened scope, HIV and AIDS wants to publish articles that deal with: 1. the pathogenesis of HIV and SIV infection and those that deal with the molecular origins of its immune activation and regulation; 2. genetics of HIV acquisition and disease; 3. HIV immunity and development of prophylactic vaccines; 4. origins and pathology of HIV associated non-AIDS diseases (for instance CVD and neuropathology) in patients on cART and their potential for immunotherapy; 5. HIV eradication therapy; 6. behavioral, social and structural factors that affect HIV risk and prevention; 7. efficacy and effectiveness of public health and combination HIV prevention approaches; 8. successful engagement with HIV treatment and care.

HIV and AIDS welcomes submissions of the following tier 1 articles: Book Review, Classification, Clinical Case Study, Clinical Trial, Editorial, General Commentary, Hypothesis & Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Review, Specialty Grand Challenge and Technology Report.

All manuscripts must be submitted directly to the section HIV and AIDS, where they are peer reviewed by the associate and review editors of the specialty section.

Articles published in the section HIV and AIDS will be subject to the Frontiers evaluation system after online publication. Authors of published original research with the highest impact, as judged democratically by the readers, will be invited by the Chief Editor to write a prestigious Frontiers Focused Review - a tier 2 article. This is referred to as "democratic tiering". The author selection is based on article impact analytics of original research published in all Frontiers specialty journals and sections. Focused Reviews are centered on the original discovery, place it into a broader context, and aim to address the wider community across all of Immunology and Public Health.

Open Access Statement

Frontiers’ philosophy is that all research is for the benefit of humankind. Research is the product of an investment by society and therefore its fruits should be returned to all people without borders or discrimination, serving society universally and in a transparent fashion.

That is why Frontiers provides online free and open access to all of its research publications. For more information on open access click here.

Copyright Statement

Under the Frontiers Conditions for Website Use and the Frontiers General Conditions for Authors, authors of articles published in Frontiers journals retain copyright on their articles, except for any third-party images and other materials added by Frontiers, which are subject to copyright of their respective owners. Authors are therefore free to disseminate and re-publish their articles, subject to any requirements of third-party copyright owners and subject to the original publication being fully cited. Visitors may also download and forward articles subject to the citation requirements and subject to any fees Frontiers may charge for downloading licenses. The ability to copy, download, forward or otherwise distribute any materials is always subject to any copyright notices displayed. Copyright notices must be displayed prominently and may not be obliterated, deleted or hidden, totally or partially. A charge may be made for some facilities (such as downloading of e-magazines), where stated.

Quality

Each Frontiers article is a landmark of the highest quality, thanks to genuinely collaborative interactions between authors and review editors, who include some of the world's best academicians. Frontiers is well aware of the potential impact of published research both on future research and on society and, hence, does not support superficial review, light review or no-review publishing models. Research must be certified by peers before entering a stream of knowledge that may eventually reach the public - and shape society. Therefore, Frontiers only applies the most rigorous and unbiased reviews, established in the high standards of the Frontiers Review System. Furthermore, only the top certified research, evaluated through the democratic Frontiers Evaluation System, is disseminated to increasingly wider communities as it gradually climbs the tiers of the Frontiers Tiering System from specialized expert readership towards public understanding.

Contact

Specialty Chief Editor/s:  John de Wit, The University of New South Wales, Australia
Frank Miedema, University Medical Centre Utrecht, Netherlands


Frontiers Editorial Office

EPFL - Innovation Square, Building I
CH – 1015 Lausanne
Switzerland

Tel +41(0)21 510 17 11
Fax +41 (0)21 510 17 01

immunology.editorial.office@frontiersin.org

Frontiers Support

Tel +41(0)21 510 17 10
Fax +41 (0)21 510 17 01

support@frontiersin.org

© 2007 - 2014 Frontiers Media S.A. All Rights Reserved